vs
Side-by-side financial comparison of Agilent Technologies (A) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.8B, roughly 1.3× Agilent Technologies). Zoetis runs the higher net margin — 26.6% vs 17.0%, a 9.6% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs 2.9%). Over the past eight quarters, Agilent Technologies's revenue compounded faster (6.9% CAGR vs -2.1%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
A vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $2.3B |
| Net Profit | $305.0M | $601.0M |
| Gross Margin | 52.6% | 71.7% |
| Operating Margin | 19.6% | — |
| Net Margin | 17.0% | 26.6% |
| Revenue YoY | 7.0% | 2.9% |
| Net Profit YoY | -4.1% | -0.2% |
| EPS (diluted) | $1.07 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | $2.3B | ||
| Q4 25 | $1.9B | $2.4B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.7B | $2.5B | ||
| Q1 25 | $1.7B | $2.2B | ||
| Q4 24 | $1.7B | $2.3B | ||
| Q3 24 | $1.6B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B |
| Q1 26 | $305.0M | $601.0M | ||
| Q4 25 | $434.0M | $603.0M | ||
| Q3 25 | $336.0M | $721.0M | ||
| Q2 25 | $215.0M | $718.0M | ||
| Q1 25 | $318.0M | $631.0M | ||
| Q4 24 | $351.0M | $581.0M | ||
| Q3 24 | $282.0M | $682.0M | ||
| Q2 24 | $308.0M | $624.0M |
| Q1 26 | 52.6% | 71.7% | ||
| Q4 25 | 53.2% | 70.2% | ||
| Q3 25 | 51.1% | 71.5% | ||
| Q2 25 | 51.9% | 73.6% | ||
| Q1 25 | 53.5% | 72.0% | ||
| Q4 24 | 53.9% | 69.5% | ||
| Q3 24 | 54.2% | 70.6% | ||
| Q2 24 | 54.4% | 71.7% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 31.9% | ||
| Q3 25 | 20.7% | 37.0% | ||
| Q2 25 | 18.0% | 36.7% | ||
| Q1 25 | 22.4% | 36.5% | ||
| Q4 24 | 24.0% | 31.6% | ||
| Q3 24 | 21.1% | 36.6% | ||
| Q2 24 | 23.1% | 33.0% |
| Q1 26 | 17.0% | 26.6% | ||
| Q4 25 | 23.3% | 25.3% | ||
| Q3 25 | 19.3% | 30.0% | ||
| Q2 25 | 12.9% | 29.2% | ||
| Q1 25 | 18.9% | 28.4% | ||
| Q4 24 | 20.6% | 25.1% | ||
| Q3 24 | 17.9% | 28.6% | ||
| Q2 24 | 19.6% | 26.4% |
| Q1 26 | $1.07 | $1.42 | ||
| Q4 25 | $1.53 | $1.37 | ||
| Q3 25 | $1.18 | $1.63 | ||
| Q2 25 | $0.75 | $1.61 | ||
| Q1 25 | $1.11 | $1.41 | ||
| Q4 24 | $1.23 | $1.29 | ||
| Q3 24 | $0.97 | $1.50 | ||
| Q2 24 | $1.05 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | — |
| Total DebtLower is stronger | $3.0B | — |
| Stockholders' EquityBook value | $6.9B | — |
| Total Assets | $12.8B | — |
| Debt / EquityLower = less leverage | 0.44× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.5B | $2.1B | ||
| Q2 25 | $1.5B | $1.4B | ||
| Q1 25 | $1.5B | $1.7B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.8B | $1.7B | ||
| Q2 24 | $1.7B | $1.6B |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $3.3B | ||
| Q3 25 | $6.4B | $5.4B | ||
| Q2 25 | $6.1B | $5.0B | ||
| Q1 25 | $6.0B | $4.7B | ||
| Q4 24 | $5.9B | $4.8B | ||
| Q3 24 | $5.9B | $5.2B | ||
| Q2 24 | $6.2B | $5.0B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $15.5B | ||
| Q3 25 | $12.2B | $15.2B | ||
| Q2 25 | $12.2B | $14.5B | ||
| Q1 25 | $11.9B | $14.1B | ||
| Q4 24 | $11.8B | $14.2B | ||
| Q3 24 | $11.0B | $14.4B | ||
| Q2 24 | $10.9B | $14.2B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | — |
| Free Cash FlowOCF − Capex | $175.0M | — |
| FCF MarginFCF / Revenue | 9.7% | — |
| Capex IntensityCapex / Revenue | 5.2% | — |
| Cash ConversionOCF / Net Profit | 0.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $893.0M | ||
| Q3 25 | $362.0M | $938.0M | ||
| Q2 25 | $221.0M | $486.0M | ||
| Q1 25 | $431.0M | $587.0M | ||
| Q4 24 | $481.0M | $905.0M | ||
| Q3 24 | $452.0M | $951.0M | ||
| Q2 24 | $333.0M | $502.0M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $732.0M | ||
| Q3 25 | $259.0M | $805.0M | ||
| Q2 25 | $107.0M | $308.0M | ||
| Q1 25 | $334.0M | $438.0M | ||
| Q4 24 | $388.0M | $689.0M | ||
| Q3 24 | $360.0M | $784.0M | ||
| Q2 24 | $230.0M | $370.0M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 30.7% | ||
| Q3 25 | 14.9% | 33.5% | ||
| Q2 25 | 6.4% | 12.5% | ||
| Q1 25 | 19.9% | 19.7% | ||
| Q4 24 | 22.8% | 29.7% | ||
| Q3 24 | 22.8% | 32.8% | ||
| Q2 24 | 14.6% | 15.7% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 6.7% | ||
| Q3 25 | 5.9% | 5.5% | ||
| Q2 25 | 6.8% | 7.2% | ||
| Q1 25 | 5.8% | 6.7% | ||
| Q4 24 | 5.5% | 9.3% | ||
| Q3 24 | 5.8% | 7.0% | ||
| Q2 24 | 6.5% | 5.6% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 1.48× | ||
| Q3 25 | 1.08× | 1.30× | ||
| Q2 25 | 1.03× | 0.68× | ||
| Q1 25 | 1.36× | 0.93× | ||
| Q4 24 | 1.37× | 1.56× | ||
| Q3 24 | 1.60× | 1.39× | ||
| Q2 24 | 1.08× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
